Nicholas Haft's most recent trade in Finch Therapeutics Group Inc was a trade of 44,843 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 13, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Finch Therapeutics Group Inc | Nicholas Haft | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 44,843 | 44,843 | - | - | Stock Option (right to buy) | |
| Finch Therapeutics Group Inc | Nicholas Haft | Director | Purchase of securities on an exchange or from another person at price $ 10.18 per share. | 20 Dec 2021 | 63,850 | 4,056,907 | - | 10.2 | 649,993 | Common Stock, $0.001 par value per share |
| Finch Therapeutics Group Inc | Nicholas Haft | Director | 23 Mar 2021 | 1,150,481 | 0 | - | - | Series D Preferred Stock | ||
| Finch Therapeutics Group Inc | Nicholas Haft | Director | 23 Mar 2021 | 1,150,481 | 1,150,481 | - | - | Common Stock | ||
| Finch Therapeutics Group Inc | Nicholas Haft | Director | 23 Mar 2021 | 1,064,466 | 1,064,466 | - | - | Common Stock | ||
| Finch Therapeutics Group Inc | Nicholas Haft | Director | 23 Mar 2021 | 1,064,466 | 0 | - | - | Series B Preferred Stock | ||
| Finch Therapeutics Group Inc | Nicholas Haft | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 23 Mar 2021 | 882,351 | 882,351 | - | 17 | 14,999,967 | Common Stock |
| Finch Therapeutics Group Inc | Nicholas Haft | Director | 23 Mar 2021 | 366,093 | 1,430,559 | - | - | Common Stock | ||
| Finch Therapeutics Group Inc | Nicholas Haft | Director | 23 Mar 2021 | 366,093 | 0 | - | - | Series C Preferred Stock | ||
| Finch Therapeutics Group Inc | Nicholas Haft | Director | 23 Mar 2021 | 212,893 | 212,893 | - | - | Common Stock | ||
| Finch Therapeutics Group Inc | Nicholas Haft | Director | 23 Mar 2021 | 212,893 | 0 | - | - | Series C Preferred Stock | ||
| Finch Therapeutics Group Inc | Nicholas Haft | Director | 23 Mar 2021 | 172,942 | 172,942 | - | - | Common Stock | ||
| Finch Therapeutics Group Inc | Nicholas Haft | Director | 23 Mar 2021 | 172,942 | 0 | - | - | Series A Preferred Stock | ||
| Finch Therapeutics Group Inc | Nicholas Haft | Director | 23 Mar 2021 | 143,831 | 143,831 | - | - | Common Stock | ||
| Finch Therapeutics Group Inc | Nicholas Haft | Director | 23 Mar 2021 | 143,831 | 0 | - | - | Series A Preferred Stock |